Immutep Limited - ADR

NASDAQ:IMMP  
2.00
+0.07 (+3.63%)
5:47:59 PM EDT: $2.10 +0.10 (+5.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)182.24M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.95 Million
Adjusted EPS-$0.16
See more estimates
10-Day MA$2.00
50-Day MA$2.04
200-Day MA$2.12
See more pivots

Immutep Limited - ADR Stock, NASDAQ:IMMP

Level 33, Australia Square, 264 George Street, Sydney, New South Wales (NSW) 2000
Australia
Phone: +61.2.8315.7003
Number of Employees:
http://www.immutep.com

Description

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK�781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.